On March 5, 2024, JonesTrading began coverage of Evaxion A/S (NASDAQ:EVAX), issuing a buy rating along with a price target of $10.00. This announcement highlights a growing interest in the company, a clinical-stage biotechnology firm based in Copenhagen, Denmark, that specializes in immunotherapies and vaccines developed through advanced AI technology.
Several other research firms have recently provided insights into Evaxion A/S’s stock. Lake Street Capital revised its price target from $11.00 to $9.00 while maintaining a buy rating. Meanwhile, Maxim Group also initiated coverage with a buy recommendation and a price objective of $10.00. In contrast, HC Wainwright reiterated a buy rating, setting a higher target of $16.00 for the stock. On the other hand, Weiss Ratings assigned a sell rating with a grade of “D-” on January 9, 2024.
Currently, five analysts have issued buy ratings for Evaxion A/S, while one has issued a sell rating. According to MarketBeat.com, the stock holds an average rating of “Moderate Buy” with an average price target of $11.00.
Recent Performance and Institutional Interest
Evaxion A/S recently reported its quarterly earnings on March 5, indicating an earnings per share (EPS) of $0.30. Analysts anticipate that the company will report an EPS of -0.15 for the current financial year, reflecting ongoing investment in research and development.
Institutional investors have shown a growing interest in Evaxion A/S. Notably, Wesbanco Bank Inc. acquired a stake valued at $48,000 during the fourth quarter. Additionally, Northwestern Mutual Wealth Management Co. purchased shares worth $38,000, while SmartHarvest Portfolios LLC invested $72,000 in the same period. Currently, institutional investors hold approximately 11.04% of the company’s stock.
About Evaxion A/S
Evaxion A/S operates at the forefront of biotechnology, leveraging a proprietary AI-based computational immunology platform. This innovative approach enables the company to identify and optimize antigen targets for therapeutic cancer vaccines and preventive vaccines against infectious diseases. By utilizing machine learning and deep learning algorithms, Evaxion analyzes extensive datasets encompassing genomic, proteomic, and immunological information to predict immune-stimulating epitopes.
As the biotechnology landscape continues to evolve, Evaxion A/S’s commitment to advancing immunotherapy solutions positions it as a key player in the industry, attracting attention from both analysts and institutional investors alike.
